Cerus Corporation (CERS)Healthcare | Medical Devices | Concord, United States | NasdaqGM
2.26 USD
|
Hot Take ↕ | Oct. 10, 2026, 7:20 a.m. EDT
Cerus Corporation presents a classic value trap scenario where the market has priced out the business entirely. The company is hemorrhaging value, with a forward P/E of -460 indicating no path to profitability soon, and a crushing 9-year cumulative decline of nearly 74%. Despite a recent revenue beat, the guidance cut sent the stock tumbling, and the balance sheet is fragile with debt exceeding cash reserves. The lack of a dividend and negative returns on equity confirm that capital is being destroyed rather than generated. The short-term outlook remains bleak due to the heavy put writing by speculators, which acts as a self-fulfilling prophecy of continued weakness. While the 52-week low offers a theoretical floor, the structural deterioration in fundamentals—negative operating margins and a shrinking market cap—suggests the stock could drift lower or stagnate for extended periods. This is not a setup for a bounce; it is a deep value trap where the 'cheap' price reflects a broken business model. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.116845 |
| AutoARIMA | 0.122625 |
| AutoETS | 0.124838 |
| AutoTheta | 0.137957 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.357 |
| Excess Kurtosis | 0.10 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 108.604 |
| Revenue per Share | 1.138 |
| Market Cap | 455,446,272 |
| Forward P/E | -452.00 |
| Beta | 1.83 |
| Profit Margins | -3.06% |
| Website | https://www.cerus.com |
As of Oct. 10, 2026, 7:20 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 1.5 and 3.0) relative to call volume. While there is some call activity at strikes 3.0 and 4.0, the overwhelming weight of options flow is defensive, suggesting a belief that the stock will struggle to recover from current lows.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.43037975 |
| Address1 | 1,220 Concord Avenue |
| Address2 | Suite 600 |
| All Time High | 81.875 |
| All Time Low | 0.55 |
| Ask | 2.76 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 1,594,990 |
| Average Daily Volume3 Month | 2,133,551 |
| Average Volume | 2,133,551 |
| Average Volume10Days | 1,594,990 |
| Beta | 1.829 |
| Bid | 2.09 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 0.348 |
| City | Concord |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.26 |
| Current Ratio | 1.834 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.32 |
| Day Low | 2.235 |
| Debt To Equity | 108.604 |
| Display Name | Cerus |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,443,400 |
| Earnings Call Timestamp Start | 1,785,443,400 |
| Earnings Timestamp | 1,785,441,600 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | 66,000 |
| Ebitda Margins | 0.00029999999 |
| Enterprise To Ebitda | 7,222.307 |
| Enterprise To Revenue | 2.152 |
| Enterprise Value | 476,672,256 |
| Eps Current Year | -0.045 |
| Eps Forward | -0.005 |
| Eps Trailing Twelve Months | -0.03 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.5454 |
| Fifty Day Average Change | -0.2853999 |
| Fifty Day Average Change Percent | -0.1121238 |
| Fifty Two Week Change Percent | 43.037975 |
| Fifty Two Week High | 3.47 |
| Fifty Two Week High Change | -1.21 |
| Fifty Two Week High Change Percent | -0.34870318 |
| Fifty Two Week Low | 1.38 |
| Fifty Two Week Low Change | 0.88 |
| Fifty Two Week Low Change Percent | 0.6376812 |
| Fifty Two Week Range | 1.38 - 3.47 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 854,721,000,000 |
| Float Shares | 195,348,160 |
| Forward Eps | -0.005 |
| Forward P E | -452.0 |
| Free Cashflow | 875,250 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 261 |
| Fullday Change | -0.00999999 |
| Fullday Change Percent | -0.44247746 |
| Fullday Price | 2.25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.52049 |
| Gross Profits | 115,315,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.036140002 |
| Held Percent Institutions | 0.73045 |
| Implied Shares Outstanding | 201,524,898 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ir Website | http://www.cerus.com/Investors/Investor-Overview/default.aspx |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California. |
| Long Name | Cerus Corporation |
| Market | us_market |
| Market Cap | 455,446,272 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_26334 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -6,783,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 523,964,734 |
| Number Of Analyst Opinions | 4 |
| Open | 2.28 |
| Operating Cashflow | 2,417,000 |
| Operating Margins | -0.03235 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 925 288 6000 |
| Pre Market Change | -0.00999999 |
| Pre Market Change Percent | -0.44247746 |
| Pre Market Price | 2.25 |
| Pre Market Time | 1,791,976,448 |
| Previous Close | 2.26 |
| Price Eps Current Year | -50.22222 |
| Price Hint | 4 |
| Price To Book | 6.494253 |
| Price To Sales Trailing12 Months | 2.0557175 |
| Profit Margins | -0.030620001 |
| Quick Ratio | 1.017 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 2.32 |
| Regular Market Day Low | 2.235 |
| Regular Market Day Range | 2.235 - 2.32 |
| Regular Market Open | 2.28 |
| Regular Market Previous Close | 2.26 |
| Regular Market Price | 2.26 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 2,293,128 |
| Return On Assets | -0.00483 |
| Return On Equity | -0.10772 |
| Revenue Growth | 0.095 |
| Revenue Per Share | 1.138 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 201,524,898 |
| Shares Percent Shares Out | 0.0872 |
| Shares Short | 17,580,423 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 17,717,716 |
| Short Name | Cerus Corporation |
| Short Percent Of Float | 0.08979999 |
| Short Ratio | 10.54 |
| Source Interval | 15 |
| State | CA |
| Symbol | CERS |
| Target High Price | 6.5 |
| Target Low Price | 4.0 |
| Target Mean Price | 5.125 |
| Target Median Price | 5.0 |
| Total Cash | 56,264,000 |
| Total Cash Per Share | 0.279 |
| Total Debt | 76,799,000 |
| Total Revenue | 221,551,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.03 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.438 |
| Two Hundred Day Average Change | -0.17799997 |
| Two Hundred Day Average Change Percent | -0.07301065 |
| Type Disp | Equity |
| Volume | 2,293,128 |
| Website | https://www.cerus.com |
| Zip | 94,520 |